These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 24783987)

  • 41. [Use of lopinavir/ritonavir monotherapy].
    Gasol Boncompte M; Padullés Zamora N; Comas Sugranyes M; Jódar Masanés R
    Farm Hosp; 2012; 36(6):561. PubMed ID: 23461460
    [No Abstract]   [Full Text] [Related]  

  • 42. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy.
    Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M; Norton M
    HIV Clin Trials; 2006; 7(5):237-45. PubMed ID: 17162317
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
    Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
    Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
    Flynn P; Komar S; Blanche S; Giaquinto C; Noguera-Julian A; Welch S; Lathouwers E; Van de Casteele T; Kakuda TN; Opsomer M
    Pediatr Infect Dis J; 2014 Sep; 33(9):940-5. PubMed ID: 25361024
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New findings bring hope to Vancouver AIDS conference.
    NIAID AIDS Agenda; 1996 Sep; ():1, 3. PubMed ID: 11363917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Can delavirdine substitute for ritonavir?
    TreatmentUpdate; 2001; 13(7):8. PubMed ID: 11794866
    [No Abstract]   [Full Text] [Related]  

  • 50. [Not Available].
    Rivero A
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():1. PubMed ID: 25542867
    [No Abstract]   [Full Text] [Related]  

  • 51. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
    Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
    Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.
    Elion R; Berger D; Richmond G; Sension M; Dejesus E; Cimoch P; St Clair M; Yau L; Ha B;
    HIV Clin Trials; 2010; 11(3):170-3. PubMed ID: 20736153
    [No Abstract]   [Full Text] [Related]  

  • 53. [HIV infection presenting with bilateral optic neuropathy].
    Laurent-Coriat C; Tilikete C; Bouhour D; Boulliat J; Fleury J; Bernard M; Vighetto A
    Rev Neurol (Paris); 2006 Jan; 162(1):95-7. PubMed ID: 16446629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
    Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
    AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nevirapine-based therapy after suppression: can we switch?
    Nachman S; McIntyre J
    Lancet Infect Dis; 2012 Jul; 12(7):498-9. PubMed ID: 22424721
    [No Abstract]   [Full Text] [Related]  

  • 57. pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.
    Brandin E; Lindborg L; Gyllensten K; Broström C; Hagberg L; Gisslen M; Tuvesson B; Blaxhult A; Albert J
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):543-50. PubMed ID: 12908931
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
    Curran A; Monteiro P; Domingo P; Villar J; Imaz A; Martínez E; Fernández I; Knobel H; Podzamczer D; Iribarren JA; Peñaranda M; Crespo M;
    J Antimicrob Chemother; 2014 May; 69(5):1390-6. PubMed ID: 24415645
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone.
    McKinnon JE; Arribas JR; Pulido F; Delgado R; Mellors JW
    AIDS; 2006 Nov; 20(18):2331-5. PubMed ID: 17117019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.